表紙
市場調査レポート

Alnylam Pharmaceuticals, Inc.:パイプライン製品の分析

Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 224581
出版日 ページ情報 英文 82 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Alnylam Pharmaceuticals, Inc.:パイプライン製品の分析 Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日: 2015年02月28日 ページ情報: 英文 82 Pages
概要

Alnylam Pharmaceuticals, Inc.は、RNA干渉法(RNAi)に基づいた新規治療薬の創薬・開発・販売に特化したバイオ医薬品企業です。同社では現在、「Alnylam 5x15」計画を推進し、遺伝子要因による疾患向けのRNAiベースの治療薬の開発に取り組んでいます。

当レポートでは、米国のバイオ医薬品企業、Alnylam Pharmaceuticals, Inc.(Alnylam)における医薬品の研究開発の進捗状況について分析し、同社の製品パイプラインの構造や、治験の全体的な進捗状況、主要なパイプライン製品のプロファイルと開発状況、同社のプロファイルと最新動向などを調査しております。

目次

Alnylam Pharmaceuticals, Inc.:現状

  • 企業概要
  • 主要情報
  • 主要データ

研究開発(R&D)の概況

  • 主な治療領域

パイプライン・レビュー

  • 開発段階別のパイプライン製品
  • パイプライン製品:単剤治療薬
  • パイプライン製品:アウトライセンス製品
    • アウトライセンス製品/併用治療モダリティ

パイプライン製品の概要

  • 後期段階のパイプライン製品
    • 第III相製品/併用治療モダリティ
  • 治験段階のパイプライン製品
    • 第II相製品/併用治療モダリティ
    • 第I相製品/併用治療モダリティ
  • 初期段階のパイプライン製品
    • 治験前製品/併用治療モダリティ
    • 創薬段階の製品/併用治療モダリティ

薬剤のプロファイル

  • patisiran
    • 製品の概要
    • 作用機序
    • 研究開発(R&D)の進展
  • ALN-TTRSC
  • asvasiran sodium
  • ALN-AT3
  • ALN-PCS02
  • ALN-PCSsc
  • ALN-TTR-01
  • ALN-VSP
  • ALN-AAT
  • ALN-ANG
  • ALN-APC
  • ALN-AS1
  • ALN-CC5
  • ALN-HPN
  • ALN-HTT
  • ALN-TMP
  • がん・ウイルス性感染症向け樹状細胞ワクチン
  • LNP-dsP21-322-2'F
  • パーキンソン病向けRNAi治療薬
  • SIRNA-034
  • 奇病向けマイクロRNA

パイプラインの分析

  • 標的別
  • 投与方法別
  • 分子の種類別
  • 作用機序別

パイプライン製品の最新動向

開発が休止状態の製品

企業のステートメント

事業所および子会社

  • 本社
  • その他の事業所・子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06822CDB

Summary

Global Markets Direct's, 'Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Alnylam Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alnylam Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Alnylam Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Alnylam Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Alnylam Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Alnylam Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Alnylam Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Alnylam Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Alnylam Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alnylam Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Alnylam Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alnylam Pharmaceuticals, Inc. Snapshot
    • Alnylam Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Alnylam Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Alnylam Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products Glance
    • Alnylam Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Alnylam Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Alnylam Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Alnylam Pharmaceuticals, Inc. - Drug Profiles
    • patisiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • revusiran
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • asvasiran sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-CC5
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AT3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-PCSsc
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-VSP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALNPCS-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AS1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AAT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AGT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-ANG
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-APC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-HBV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-HPN
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-HTT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-PDL
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-TMP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALNAC-3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALNGO-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy for Cancer and Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dsP21-322-2'F
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-HDV
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for Cardiovascular and Metabolic Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for Genetic Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotides for Hepatic Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alnylam Pharmaceuticals, Inc. - Pipeline Analysis
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Target
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Alnylam Pharmaceuticals, Inc. - Dormant Projects
  • Alnylam Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alnylam Pharmaceuticals, Inc., Key Information
  • Alnylam Pharmaceuticals, Inc., Key Facts
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Alnylam Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Alnylam Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Alnylam Pharmaceuticals, Inc. - Phase III, 2015
  • Alnylam Pharmaceuticals, Inc. - Phase II, 2015
  • Alnylam Pharmaceuticals, Inc. - Phase I, 2015
  • Alnylam Pharmaceuticals, Inc. - IND/CTA Filed, 2015
  • Alnylam Pharmaceuticals, Inc. - Preclinical, 2015
  • Alnylam Pharmaceuticals, Inc. - Discovery, 2015
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Alnylam Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Alnylam Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Alnylam Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Alnylam Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top